Vol. 2 No. 9 (2022): September
Reimbursement Recommendations

Pembrolizumab (Keytruda) in Combination With Lenvatinib (Lenvima)

Published September 20, 2022

Key Messages

  • CADTH recommends that Keytruda in combination with Lenvima (Keytruda-Lenvima) should be reimbursed by public drug plans for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation if certain conditions are met.
  • Keytruda-Lenvima should only be covered in patients with endometrial cancer that has spread to the pelvis or other body parts, that is classified as proficient mismatch repair (pMMR), and has further spread after 1 prior systemic, platinum-based chemotherapy.
  • Keytruda-Lenvima should only be reimbursed if prescribed in an outpatient oncology clinic or institution with expertise in delivering systemic therapy, when administered in combination, and if the cost is reduced.